Saroglitazar

DRUG4 trials

Sponsors

Command Hospital, India, Zydus Therapeutics Inc., Asian Institute of Gastroenterology, India, Zydus Lifesciences Limited

Conditions

DyslipidemiasFatty LiverLiver Transplant; ComplicationsMetabolic SyndromeNAFLDObesityType 2 Diabetes

Phase 2

Safety, Tolerability, and Efficacy of Saroglitazar Mg 4 mg in Liver Transplant Recipients With Nonalcoholic Fatty Liver Disease (NAFLD)

CompletedNCT03639623

Zydus Therapeutics Inc.Liver Transplant; Complications, NAFLD

Start: 2019-02-25End: 2021-12-13Updated: 2024-10-24

Phase 3

A Prospective, Randomized Trial to Compare saroGLitazar With pioglitAZone in Nonalcoholic Fatty livEr Disease

Command Hospital, IndiaFatty Liver

Start: 2014-10-31End: 2015-09-30Target: 100Updated: 2014-10-16

An Investigator Initiated Prospective, Four Arms Randomized Comparative Study of Efficacy and Safety of Saroglitazar, Vitamin E and Life Style Modification in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)/ Non-alcoholic Steatohepatitis (NASH)

Asian Institute of Gastroenterology, IndiaNAFLD

Start: 2021-01-31End: 2021-10-31Target: 250Updated: 2021-01-26

Phase 4

A Study to Evaluate the Safety and Effectiveness of Saroglitazar 4 mg in Patients With NAFLD With Comorbidities

RecruitingNCT05872269

Zydus Lifesciences LimitedDyslipidemias, Metabolic Syndrome, NAFLD +2

Start: 2023-07-20End: 2025-06-10Target: 1500Updated: 2024-02-07